Tumor Location Shapes Leiomyosarcoma Survival Outcomes
A study of 11,700 patients found survival for this rare cancer varies substantially by where the tumor develops in the body.
Updated on Nov. 2, 2026 in Cancer
University of Edinburgh scientists analyzed 11,700 leiomyosarcoma patients and found survival differs by tumor location. Uterine, urinary tract and trunk tumors had the poorest survival rates, while limb, head and neck, and male reproductive tract tumors fared better.
Why it matters
Tumor location may offer clinically meaningful information on disease risk beyond stage and grade, and accounting for it may be important when interpreting trials of new therapies. The findings could support more personalized approaches to treatment.
The analysis drew on survival records for 11,700 leiomyosarcoma patients, a cohort large enough to compare outcomes across body sites. Uterine tumors were more likely than tumors elsewhere to carry a specific genetic mutation, but it remains unclear whether this mutation explains the survival gap.
The players
University of Edinburgh
A leading Scottish research university whose scientists led the leiomyosarcoma survival study.
Cancer Research UK
The United Kingdom's largest independent cancer research charity, which funded the study alongside Sarcoma UK.
Sarcoma UK
A UK charity dedicated to supporting sarcoma patients and funding research into these rare cancers.
The details
Leiomyosarcoma affects smooth muscle cells in the walls of hollow organs and blood vessels, and it commonly arises in the uterus, limbs and abdomen. The researchers also found that Black patients, patients from lower-income households and widowed individuals had significantly poorer outcomes, and noted that clinical trials of the cancer are often conducted without accounting for tumor location.
Timeline
The study was published in the Journal of the National Cancer Institute in 2026.
Health Landscape
The study builds on Cancer Research UK's longstanding funding of sarcoma research, which has increasingly treated rare cancers as distinct biological entities. Its finding that tumor site shapes survival challenges the practice of pooling leiomyosarcomas together in clinical trials.
Patients with leiomyosarcoma may have their prognosis better understood by considering where their tumor is located rather than stage alone. Clinicians may also begin accounting for tumor site when weighing the results of new treatment studies.
The takeaway
Where a cancer begins can matter as much as how far it has spread, so clinicians and patients may benefit from asking about tumor location. Taking site into account could make future leiomyosarcoma research and treatment decisions more precise.
Further reading
Explore more on Cancer research and survival trends.
More information
Read the full JNCI leiomyosarcoma survival study in the Journal of the National Cancer Institute.
Source note: This article includes information reported by Selectscience.
